IPOPEMA Securities, a brokerage house, has published an analytical report on Medicalgorithmics, starting its coverage of the company. Ipopema Securitas has issued a BUY recommendation with a target price of 45.2 PLN per share, indicating a 26% upside from the stock’s price on September 6th.
Ipopema Securities highlighted in its analytical report that “Medicalgorithmics has significantly changed over the past year: it has acquired a new strategic shareholder Biofund, is cash rich, has a new business unit Kardiolytics, and has reinvented its strategy for the ECG business.”
The complete Ipopema Securities report is available for download at the following link: https://www.ipopemasecurities.pl/media/files/analizy-medicalgorithmics-a-new-hope.pdf